Innovating Works

SANOFI PASTEUR SA

Desconocido
Inno4Vac: Innovations to accelerate vaccine development and manufacture SANOFI PASTEUR SA participó en un H2020 H2020-JTI-IMI2-2020-20-two-stage Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling...
2021-07-19 - 2027-02-28 | Financiado
PROMISE: Preparing for RSV Immunisation and Surveillance in Europe SANOFI PASTEUR SA participó en un H2020 H2020-JTI-IMI2-2020-22-single-stage RSV causes severe disease in the very young and elderly and results in substantial healthcare costs. In the last 4 years, substantial progre...
2021-05-21 - 2024-04-30 | Financiado
VITAL: Vaccines and Infectious Diseases in the Ageing PopuLation SANOFI PASTEUR SA participó en un H2020 H2020-JTI-IMI2-2017-12-two-stage Today’s major challenge is to improve efficacy of vaccines to protect the growing ageing population against infectious diseases (ID). The VI...
2018-12-10 - 2024-12-31 | Financiado
COMBACTE-CDI: Combatting Bacterial Resistance in Europe Clostridium Difficile Infections SANOFI PASTEUR SA participó en un H2020 H2020-JTI-IMI2-2016-09-two-stage Clostridium difficile infection (CDI) is one of the most prevalent healthcare associated infections, affecting both hospitalized patients an...
2017-10-27 - 2021-04-30 | Financiado
DRIVE: Development of Robust and Innovative Vaccine Effectiveness SANOFI PASTEUR SA participó en un H2020 H2020-JTI-IMI2-2016-09-two-stage Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the...
2017-08-08 - 2022-06-30 | Financiado
RESCEU: REspiratory Syncytial virus Consortium in EUrope Sofia ref. 116019 SANOFI PASTEUR SA participó en un H2020 H2020-JTI-IMI2-2015-06-two-stage RSV causes severe disease and results in substantial healthcare costs in individuals at the extremes of the age spectrum and in high risk gr...
2016-12-14 - 2022-09-30 | Financiado
PERISCOPE: PERtussIS COrrelates of Protection Europe Sofia ref. 115910 SANOFI PASTEUR SA participó en un H2020 H2020-JTI-IMI2-2015-03-two-stage Pertussis vaccines have been very successful in reducing the global burden of pertussis-related disease. However, in the last decade there h...
2016-08-01 - 2022-08-31 | Financiado
VAC2VAC: Vaccine lot to Vaccine lot comparison by consistency testing. SANOFI PASTEUR SA participó en un H2020 H2020-JTI-IMI2-2015-03-two-stage Lot release testing of established vaccines relies on using animal models. Many of these models were developed decades ago and reflect the l...
2016-04-14 - 2022-02-28 | Financiado
EHVA: European HIV Vaccine Alliance EHVA a EU platform for the discovery and evaluation of novel prophy... SANOFI PASTEUR SA participó en un H2020 H2020-PHC-2014-2015 Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. T...
2015-12-17 - 2023-12-31 | Financiado
FLUCOP: Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protect... SANOFI PASTEUR SA tramitó un FP6 Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Infl...
2015-03-01 - 2020-02-29 | Financiado
ADVANCE: Accelerated Development of Vaccine benefit-risk Collaboration in Europe SANOFI PASTEUR SA participó en un FP6 Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to...
2013-10-01 - 2019-03-31 | Financiado
BIOVACSAFE: Biomarkers For Enhanced Vaccine Safety SANOFI PASTEUR SA participó en un FP6 BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised...
2012-03-01 - 2018-08-31 | Financiado
FLUCOP: Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protect... SANOFI PASTEUR SA tramitó un FP7 Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Infl...
Financiado
EURONEUT-41: EUROpean consortium on NEUTralising antibodies using gp41 SANOFI PASTEUR SA tramitó un FP7 There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, pept...
Financiado
STOPENTERICS: Vaccination against Shigella and ETEC novel antigens novel approaches SANOFI PASTEUR SA participó en un FP7 To contribute to the development of vaccines against Shigella and ETEC for children of the developing world, STOPENTERICS will provide novel...
Financiado
ADVANCE: Accelerated Development of Vaccine benefit risk Collaboration in Europe SANOFI PASTEUR SA participó en un FP7 Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to...
Financiado
BIOVACSAFE: Biomarkers For Enhanced Vaccine Safety SANOFI PASTEUR SA participó en un FP7 BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.